Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide in Metastasized Neuroendocrine Tumors of the Midgut
NCT00171873Phase 3Completed
- Start
- Sep 2001
- Primary completion
- Jun 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neuroendocrine Neoplasm (NEN) comparing Octreotide LAR with Placebo (2 arms). Primary endpoint: Time to Tumor Progression at 7 years. Started Sep 2001; status: completed.
02
Drugs
Octreotide long-acting injection
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00171873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171873.